Repligen To Host Investor Day 2022
24 août 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen...
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
02 août 2022 07h30 HE
|
Repligen Corporation
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong organic revenue growth of 29% and strong base...
Repligen to Report Second Quarter 2022 Financial Results
19 juil. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2,...
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
26 mai 2022 16h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and...
Repligen Corporation to Present at Upcoming Investor Conferences
25 mai 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
27 avr. 2022 07h30 HE
|
Repligen Corporation
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base...
Repligen to Report First Quarter 2022 Financial Results
13 avr. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27,...
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
18 mars 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
17 févr. 2022 07h30 HE
|
Repligen Corporation
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic...
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
15 févr. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...